Clinical Trials on Human Influenza

Total 8078 results

GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

Influenza

United States, Canada
Kaiser Permanente
Centers for Disease Control and Prevention

Completed

A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

Influenza

United States
Alios Biopharma Inc.

Completed

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Influenza

United Kingdom
University of Oxford

Completed

ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses

Influenza

United Kingdom
Rambam Health Care Campus

Completed

The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection

Influenza

Israel
Johns Hopkins University
Department of Health and Human Services

Completed

Influenza Diagnosis, Treatment and Surveillance With Xpert Flu

Influenza

United States
Nitto Denko Corporation

Completed

Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers

Influenza

Japan
Changchun BCHT Biotechnology Co.
National Institutes for Food and Drug Control, China; Simoon Record Pharma... and other collaborators

Completed

A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

Influenza

China
National University Hospital, Singapore
Sanofi Pasteur, a Sanofi Company; National University, Singapore; Agency for...

Completed

The Immune Response to Influenza Vaccinations in Elderly Individuals

Influenza

Singapore
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Dose Study of Peramivir for Influenza Treatment

Influenza

United States
University of Pittsburgh
Sanofi Pasteur, a Sanofi Company

Completed

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years

Influenza, Human

United States
GlaxoSmithKline
ID Biomedical Corporation, Quebec

Completed

Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

Influenza
Baylor College of Medicine
National Institute of Allergy and Infectious Diseases (NIAID); Novartis; Sanofi... and other collaborators

Completed

Control of Epidemic Influenza Through a School-based Influenza Vaccination Program (CEI)

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' FluLaval® TF

Influenza

Belgium
GlaxoSmithKline

Completed

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

Influenza

Germany, United States, Belgium, Norway
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Human Mucosal Immune Responses to Influenza Virus (SLVP026)

Influenza
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months

Influenza

Guatemala
Hoffmann-La Roche

Terminated

A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.

Influenza

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.

Influenza

Mexico
Research Institute for Biological Safety Problems
Research Institute of Influenza, Russia; Asfendiyarov Kazakh National Medical...

Completed

Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)

Influenza, Human

Kazakhstan
GlaxoSmithKline

Completed

Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Influenza

Japan
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects

Influenza

Italy
Hoffmann-La Roche

Completed

Influenza Resistance Information Study (IRIS)

Influenza

Australia, Hong Kong, United States, France, Germany, Netherlands, Norway, Poland
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults

Influenza

Belgium
Novavax
Department of Health and Human Services

Completed

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Influenza

United States
Children's Hospital Los Angeles
Los Angeles County Department of Public Health

Completed

Study to Evaluate Impact of School-based Influenza Vaccination on School Populations

Influenza

United States
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Influenza

China
Hoffmann-La Roche

Completed

A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza

Influenza

United States, Lebanon, Israel
National Institute of Allergy and Infectious Diseases...

Completed

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

Influenza

United States
Hoffmann-La Roche

Terminated

A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza

Influenza

United States, Israel
Seqirus

Completed

Phase II Study of Pandemic Influenza Vaccine

Influenza

Australia
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Influenza A 2009 H1N1 Challenge Study in Healthy Adults

Influenza

United States
The University of Hong Kong

Completed

Impact of Patient Education on Influenza Vaccine Uptake Among Community-dwelling Chinese Elderly

Influenza, Human
Hoffmann-La Roche

Completed

A Retrospective, Observational Registry of Participants With Avian Influenza Infection

Influenza
Sanofi Pasteur, a Sanofi Company

Completed

Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Trial to Collect Safety Data and Sera for Immunogenicity Testing

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

Influenza

United States

3

Subscribe